Improving Spirometry Diagnostic Reliability in Viet Nam: Test Acceptability, Repeatability and Clinical Interpretation

MEASUREMENT, LEARNING & IMPROVEMENTDIAGNOSTIC SAFETY & RISK MANAGEMENT

11/5/202623 min read

Improving Spirometry Diagnostic Reliability in Viet Nam: Test Acceptability, Repeatability and Clinical Interpretation

A patient completes a spirometry examination, receives a printed report and leaves the clinic. The numerical values look precise, the graphs appear complete and the software has generated an interpretation. Yet an important question may remain unanswered: were the measurements technically reliable enough to support the conclusion?

A patient who does not begin exhaling forcefully enough may produce an underestimated forced expiratory volume in one second. Another who stops exhaling prematurely may have an underestimated forced vital capacity. Even when several attempts produce similar values, the measurements may not adequately represent the patient's lung function if the same technical problem occurred during each maneuver.

These differences matter because spirometry is widely used to investigate respiratory symptoms, identify patterns of airflow limitation, support clinical diagnosis and monitor changes in lung function over time. Unreliable measurements can contribute to diagnostic misclassification, unnecessary investigations, inappropriate treatment or delayed recognition of respiratory disease.

Improving spirometry reliability requires more than purchasing suitable equipment. Healthcare organizations need competent operators, standardized examination procedures, systematic assessment of technical quality and clinically appropriate interpretation.

The choice of reference equations also matters. A technically acceptable measurement can receive different interpretations depending on the reference framework used. Changing that framework may alter the classification of a patient's results without any change in actual lung function.

Recent international guidance and research published in 2026, including a study conducted in Viet Nam, provide an opportunity to examine how these issues are managed in routine practice.

For healthcare organizations in Viet Nam, the objective should not simply be to perform more spirometry examinations. It should be to ensure that measurements are sufficiently reliable for their intended purpose and that their limitations are recognized before clinical decisions are made.

Why Spirometry Quality Matters for Diagnostic Safety

Spirometry measures aspects of pulmonary function through breathing maneuvers performed under standardized conditions.

Two commonly reported measurements are forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). Their relationship, expressed as the FEV1/FVC ratio, provides information about expiratory airflow limitation.

These measurements reflect physiological characteristics, but they are also influenced by the patient's understanding of instructions, physical ability, coordination and effort during the examination.

Unlike many automated laboratory examinations, spirometry requires active participation from the person being tested. The operator must explain the procedure, provide effective coaching, recognize inadequate maneuvers and determine whether the results satisfy the relevant technical criteria.

An insufficiently forceful start can underestimate FEV1. Premature termination of expiration can underestimate FVC. Coughing, air leakage, glottic closure or obstruction of the mouthpiece can also compromise measurement reliability.

The resulting values may still appear plausible. For example, an artificially reduced FVC caused by incomplete expiration could be mistaken for a finding suggesting restrictive ventilatory impairment. An underestimated FVC may also increase the calculated FEV1/FVC ratio, potentially making airflow obstruction less apparent.

These problems illustrate why the apparent precision of a numerical result should not be confused with confidence in its accuracy.

The American Thoracic Society (ATS) and European Respiratory Society (ERS) addressed these concerns in their 2019 technical statement, Standardization of Spirometry 2019 Update.

The standard provides detailed recommendations concerning equipment, calibration verification, operator competence, patient preparation, test performance, acceptability, repeatability and reporting.

Its central contribution is a systematic approach to establishing the technical quality of an examination rather than assuming reliability simply because a spirometer has produced numerical results.

Test Acceptability: Can the Individual Maneuver Be Trusted?

The first question in spirometry quality assurance is whether each breathing maneuver satisfies the relevant technical criteria.

The ATS/ERS 2019 standard evaluates several aspects of forced expiration, including the quality of the initial effort, the presence of artifacts affecting measurement and the completeness of expiration.

A satisfactory start is particularly important for FEV1. The patient needs to begin expiration rapidly and forcefully after reaching full inspiration. A hesitant start can underestimate FEV1 even when the patient subsequently continues exhaling for an adequate duration.

Coughing during the first second can also compromise FEV1. Other problems, including air leakage, glottic closure and obstruction of the mouthpiece, may affect the reliability of recorded measurements.

The end of forced expiration is especially important for FVC.

A patient may stop exhaling before reaching the maximum volume that could be expelled. The recorded FVC may then underestimate the patient's actual forced vital capacity.

The ATS/ERS standard identifies three alternative indicators for an acceptable end of forced expiration: an appropriate expiratory plateau, a forced expiratory time of at least 15 seconds or an FVC measurement consistent with the largest previously observed value within the applicable repeatability criteria.

These alternatives recognize that patients do not all have the same expiratory pattern. Some may reach a plateau rapidly, while others with airflow obstruction may require more time to complete expiration.

Importantly, the standard does not establish a universal minimum expiratory duration that every patient must achieve before a maneuver can be accepted. Requiring unnecessarily prolonged expiration may introduce fatigue, discomfort or other problems without improving clinical interpretation.

FEV1 and FVC also have related but distinct acceptability requirements.

A maneuver may provide an acceptable or usable FEV1 even when FVC is not acceptable because expiration ended prematurely. Conversely, certain technical disturbances may compromise FEV1 without necessarily invalidating the FVC measurement.

The 2019 standard therefore distinguishes acceptable measurements from usable measurements.

This distinction avoids an unnecessarily rigid approach in which every imperfect maneuver is either accepted without qualification or discarded entirely.

A patient with severe respiratory impairment, frailty or difficulty following instructions may be unable to achieve the highest technical quality grade despite appropriate support. Some measurements may nevertheless remain informative when their technical limitations are understood.

The appropriate response is to determine which measurements can be used, how much confidence they support and whether further assessment is necessary.

Repeatability: Why Consistency Does Not Guarantee Accuracy

Repeatability provides another important measure of spirometry quality.

It describes how closely selected measurements agree when the patient performs multiple maneuvers during the same testing session. Its purpose is to help establish whether the recorded values reasonably represent the patient's best performance under the examination conditions.

A single apparently acceptable maneuver is not normally sufficient to establish satisfactory session quality.

For patients older than six years, the ATS/ERS 2019 standard generally defines satisfactory repeatability as a difference of no more than 150 mL between the two largest acceptable FEV1 values and, separately, between the two largest acceptable FVC values.

For children aged six years or younger, the corresponding criterion is generally 100 mL or 10% of the largest value, whichever is greater.

These are technical performance criteria, not diagnostic thresholds separating people with and without respiratory disease.

Repeatability should also be distinguished from changes in lung function measured on different days. A patient may produce closely matching results during one session but show different measurements at a later appointment because of biological variation, medication effects, changes in clinical condition or differences in examination technique.

More importantly, repeatability does not guarantee accuracy.

A patient who repeatedly stops exhaling prematurely may produce similar FVC values across several maneuvers. The agreement between those measurements does not necessarily establish that maximal forced vital capacity was achieved.

This is why repeatability must be considered alongside maneuver acceptability.

The ATS/ERS 2019 quality grading system combines these elements to describe confidence in the testing session. FEV1 and FVC are graded separately because their technical quality may differ.

The system includes grades A through F, together with grade U for results that remain usable despite the absence of fully acceptable measurements.

Higher grades generally support greater confidence in the reported values. Lower grades require more cautious interpretation, particularly when measurements are close to clinically important thresholds.

However, a grade below A does not automatically mean that the examination has no clinical value. The significance of the grade depends on which measurements are acceptable or usable, the degree of repeatability and the clinical question being investigated.

The standard also recognizes that the largest acceptable FEV1 and the largest acceptable FVC may come from different maneuvers. The reported FEV1/FVC ratio is calculated using these selected values according to the standardized reporting approach.

Automated quality grading can support consistent practice, but testing services should understand the criteria used by their devices.

A device-generated label should not replace professional review when the recorded curves, patient performance or technical circumstances suggest that the underlying assessment may be unreliable.

Equipment Quality, Operator Competence and Patient Preparation

Even a well-designed quality grading system cannot compensate for poorly maintained equipment or inconsistent examination procedures.

Spirometers require appropriate performance verification, maintenance and quality control.

The ATS/ERS 2019 standard includes recommendations concerning equipment accuracy, calibration verification, environmental conditions and other technical factors that may influence measurements.

ISO 26782:2009 establishes international equipment requirements for spirometers intended to measure timed forced expiratory volumes.

As of November 2026, the 2009 edition remains the published international standard, while a revised edition is under development.

Equipment standards and clinical testing standards address different aspects of quality. A spirometer that meets technical specifications does not guarantee that every examination performed with it will produce acceptable measurements.

Healthcare organizations should establish equipment procedures consistent with validated manufacturer instructions and relevant professional standards.

Repeated calibration verification failures, unexpected measurement drift, damaged components or software problems should prompt appropriate investigation before the device is returned to routine clinical use.

Operator competence is equally important.

A trained operator needs to recognize insufficient initial effort, premature expiration, coughing, leakage and other technical problems while the examination is being performed.

Effective coaching can improve test quality, but it should be adapted to the patient's physical ability, understanding, communication needs and clinical condition.

Simply repeating instructions or asking for stronger efforts is not always appropriate.

Patients may experience fatigue, dizziness, discomfort or difficulty completing repeated forced breathing maneuvers. Relevant contraindications and clinical risks should be considered before testing, and the procedure should be stopped when patient safety requires it.

The ATS/ERS standard generally aims to obtain at least three acceptable FEV1 and FVC measurements, subject to patient circumstances, and identifies eight forced expiratory maneuvers as a practical upper limit for most adults. More attempts may sometimes be appropriate in children.

The number of attempts should not become an inflexible target that overrides patient safety or the likely value of further testing.

Patient preparation also affects reliability.

Depending on the examination's purpose, relevant factors may include recent physical activity, smoking, respiratory medication use and the timing of bronchodilator administration.

An examination intended to assess lung function under usual treatment conditions is not necessarily equivalent to one performed after selected bronchodilators have been withheld under an appropriate testing protocol.

Medication conditions should therefore be documented when relevant, particularly when comparing results over time.

Reliable spirometry depends on coordination among equipment quality assurance, operator competence, patient preparation and appropriate clinical oversight.

Clinical Interpretation Begins With Measurement Quality

Once spirometry has been performed, the next question is what the measurements mean.

The ERS/ATS technical standard on interpretive strategies for routine lung function tests, published in 2022, emphasizes that interpretation must consider biological variability, measurement uncertainty, appropriate reference values and clinical context.

This matters because spirometry describes physiological patterns. It does not independently establish the diseases responsible for those patterns.

A reduced FEV1/FVC ratio may indicate airflow obstruction under the applicable interpretive framework. However, it does not, by itself, determine whether the patient has COPD, asthma or another condition affecting expiratory airflow.

Similarly, a reduced FVC may raise suspicion of restrictive ventilatory impairment, but spirometry alone generally cannot confirm a restrictive ventilatory defect.

Confirmation requires appropriate measurement of total lung capacity.

A low FVC can also result from air trapping, incomplete expiration or other physiological and technical circumstances. Interpreting every reduced FVC as confirmed restrictive lung disease can therefore contribute to diagnostic misclassification.

The flow-volume and volume-time curves provide information that numerical values alone may not reveal. They can help identify unusual patterns, early termination, inadequate effort and other limitations that affect confidence in the measurements.

A comprehensive interpretation should consider these graphical findings alongside FEV1, FVC, the FEV1/FVC ratio, reference equations, technical quality and the patient's clinical presentation.

Previous measurements may also provide useful context, especially when the purpose is to assess changes over time.

The report should distinguish physiological findings from clinical diagnoses. Describing an obstructive ventilatory pattern is not equivalent to confirming COPD without considering relevant symptoms, exposure history and diagnostic criteria.

Technical quality also needs to be interpreted according to the purpose of testing.

A lower-grade examination may still provide useful evidence about whether airflow obstruction is present, even when it is insufficiently precise for other purposes, such as monitoring a small change in lung function.

Conversely, a technically limited result near a diagnostic threshold may not support the same level of confidence as a high-quality examination.

The strength of a clinical conclusion should reflect both the reliability of the measurement and the available clinical evidence.

Reference Equations Can Change the Meaning of the Same Measurement

Spirometry results are commonly interpreted by comparing measured values with reference equations derived from populations without known relevant respiratory disease.

These equations use characteristics such as age, height and sex to calculate predicted values, lower limits of normal and standardized scores.

However, different reference equations can produce different interpretations of the same measured lung function.

A result classified as within the expected range under one equation may fall outside that range under another.

The patient's actual measurement has not changed. What has changed is the statistical framework used to interpret it.

Historically, some widely used reference equations incorporated race- or ethnicity-based categories.

In 2023, the ATS published an official statement recommending a race-neutral approach to pulmonary function test interpretation, including consideration of the Global Lung Function Initiative's race-neutral GLI Global reference equations.

The statement raised concerns that race-based adjustments could normalize differences associated with unequal environmental and social exposures, potentially contributing to inequities in respiratory diagnosis and management.

The ATS also recognized uncertainty about the consequences of changing reference equations and the need for further research in diverse populations.

These considerations are relevant to healthcare organizations in Viet Nam.

Reference equations developed from international datasets may not fully represent the distribution of lung function in every population receiving care locally. However, the absence of comprehensive Vietnamese population-specific outcome data does not, by itself, establish that a race-based equation is preferable.

Healthcare organizations should understand the scientific basis, limitations and potential consequences of the reference framework they adopt.

Consistency also matters when comparing results over time.

A patient's percentage-predicted FEV1 or z-score may change after a software update or reference equation transition even though the measured FEV1 remains identical.

Such differences should not be mistaken for physiological deterioration or improvement.

When adopting new reference equations, organizations should evaluate their effects on reporting, clinical interpretation and comparisons with historical results.

Evidence From Viet Nam: Why Reference Equation Selection Matters

A study published online on September 10, 2026, in Respiratory Medicine provides relevant evidence from Viet Nam.

Tran and colleagues investigated the effects of changing from the earlier ethnicity-specific GLI-2012 reference framework to the race-neutral GLI-2022 framework in patients undergoing spirometry at Vinmec Central Park Hospital in Ho Chi Minh City.

The cross-sectional study included 265 consecutive patients of Southeast Asian origin who underwent pre-bronchodilator spirometry.

The investigators interpreted the same measurements using both reference frameworks and examined how classification patterns changed.

Overall agreement between the systems was relatively high. Nevertheless, 29 of the 265 participants, approximately 10.9%, changed their classified spirometric pattern under the alternative reference framework.

GLI-2022 produced higher predicted FEV1 and FVC values and lower predicted FEV1/FVC values in the study population. These changes resulted in lower FEV1 and FVC z-scores and higher FEV1/FVC z-scores.

The proportion classified as having airflow obstruction decreased from 7.55% to 4.15%, while the proportion classified as having possible restriction or a nonspecific pattern increased from 20.75% to 27.92%.

These findings demonstrate that reference equation selection can materially affect the interpretation of spirometry in a Vietnamese healthcare setting.

However, the study has important limitations.

It was conducted at one tertiary hospital and involved a relatively small cohort undergoing pre-bronchodilator testing. The research evaluated differences between classification frameworks rather than establishing which framework more accurately predicts clinical outcomes.

It did not determine whether changing reference equations improves diagnosis, treatment decisions or long-term patient outcomes.

The observed 10.9% reclassification rate should therefore not be presented as a national estimate for Viet Nam.

Nor does a change in classification necessarily mean that the earlier or revised interpretation was incorrect.

The study supports a more specific conclusion: changing reference equations can alter the reported physiological classification of the same measurements, and the clinical consequences of that change require careful assessment.

For healthcare organizations considering a transition to race-neutral equations, this provides a reason to examine how existing results may be affected, which clinical groups are most likely to be reclassified and how the changes should be explained to clinicians.

It also demonstrates the value of locally relevant research in evaluating international diagnostic recommendations.

GOLD and GLI in 2026: Beyond the Debate About Diagnostic Thresholds

In 2026, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Lung Function Initiative (GLI) published a joint statement concerning the use of spirometry to define airflow obstruction and support COPD diagnosis.

Published in the European Respiratory Journal, the statement addresses the long-standing debate between fixed-ratio and lower-limit-of-normal approaches.

GOLD has traditionally recommended a post-bronchodilator FEV1/FVC ratio below 0.70 to identify persistent airflow obstruction in patients whose clinical history is suggestive of COPD.

The ERS/ATS interpretive framework and GLI have emphasized the lower limit of normal, which accounts for expected physiological variation associated with age and other relevant characteristics.

The approaches are not identical.

A fixed threshold may classify an older individual as having airflow obstruction even when the measured ratio remains within the age-adjusted reference range.

Conversely, a younger individual may have an FEV1/FVC ratio below the lower limit of normal without falling below the fixed threshold of 0.70.

The joint statement acknowledges the limitations of both approaches and emphasizes areas of agreement that are important for clinical practice.

GOLD and GLI agree that spirometry provides essential objective information about airflow obstruction and that, in an appropriate clinical context, the fixed post-bronchodilator ratio can be used to identify COPD-related airflow obstruction and support confirmation of COPD.

They also agree that spirometry alone is insufficient to establish a clinical diagnosis of COPD.

Relevant symptoms, exposure history, other clinical findings and the reliability of the examination must be considered.

The statement recognizes that measurement error and biological variability create uncertainty, particularly when values lie near diagnostic thresholds.

When the fixed-ratio and lower-limit-of-normal approaches disagree, or when measurements fall within a clinically uncertain range, further evaluation may be appropriate.

Depending on the clinical situation, this may involve repeat spirometry, additional physiological measurements or other investigations.

These considerations should not be reduced to a requirement to repeat every borderline examination automatically. The need for further testing depends on the patient's symptoms, prior probability of disease, examination quality and consequences of diagnostic uncertainty.

The statement also highlights an important practical distinction concerning test quality.

When FEV1, FVC and FEV1/FVC are within the expected range and the fundamental technical requirements have been met, such results can provide meaningful evidence against COPD as currently defined, even if the examination has not achieved the highest quality grade.

However, a patient with persistent respiratory symptoms or a strong clinical suspicion of disease may still require further evaluation.

This reinforces the need to assess spirometry quality according to the clinical question rather than applying a simplistic rule that every examination below grade A is unusable.

Debating whether the diagnostic threshold should be 0.70 or based on the lower limit of normal is less useful when the underlying measurements are unreliable.

For diagnostic quality, numerical thresholds must be applied to sufficiently reliable measurements and interpreted within the clinical circumstances for which they were intended.

Bronchodilator Responsiveness Is Not the Same as Reversibility

Spirometry may be performed before and after administration of a bronchodilator to evaluate changes in expiratory airflow and lung volumes.

This provides useful physiological information, but its reliability depends on the quality of both measurement sets.

Pre-bronchodilator and post-bronchodilator maneuvers should be assessed separately for acceptability and repeatability.

If the baseline examination is technically inadequate, an apparent improvement after bronchodilator administration may partly reflect better effort, improved coordination or more complete expiration rather than a true physiological response.

The opposite problem can occur when the post-bronchodilator examination is of poorer technical quality than the baseline assessment.

The ERS/ATS 2022 interpretive standard updated the recommended approach to evaluating bronchodilator responsiveness.

Under that framework, a change in FEV1 or FVC greater than 10% of the individual's predicted value is considered a significant bronchodilator response.

This is not equivalent to a 10% change relative to the measured pre-bronchodilator value.

The distinction matters because the denominator affects whether a response crosses the interpretive threshold.

The 2026 GOLD/GLI statement also discusses the difference between bronchodilator responsiveness and bronchodilator reversibility.

Bronchodilator responsiveness describes the magnitude of change in FEV1 or FVC following administration of a bronchodilator.

Bronchodilator reversibility refers to normalization of previously demonstrated airflow obstruction after bronchodilator administration, according to the relevant interpretive threshold.

A patient may demonstrate a substantial bronchodilator response while continuing to have airflow obstruction.

Conversely, the absence of a significant bronchodilator response during one examination does not automatically exclude asthma or establish COPD.

These distinctions are important because simplified software interpretations can encourage clinicians to treat a physiological response as a disease-specific conclusion.

A reliable report should describe the measured response, the interpretive criteria used and any relevant technical limitations without claiming more diagnostic certainty than the examination supports.

Reporting Technical Quality and Diagnostic Uncertainty

A spirometry report should allow the receiving clinician to understand both the physiological findings and the reliability of the measurements.

A report containing only FEV1, FVC, the FEV1/FVC ratio and an automated conclusion may omit information needed to assess confidence in the result.

Depending on the examination and clinical setting, relevant information may include the technical quality grade, reference equation, patient characteristics used for prediction, pre-bronchodilator or post-bronchodilator status and important limitations affecting interpretation.

Access to the flow-volume and volume-time curves can support independent review, particularly when unexpected findings may influence an important clinical decision.

Operator observations may also provide useful context.

For example, documentation that a patient experienced repeated coughing, could not sustain expiration or became fatigued may help explain why the examination did not achieve a high quality grade.

These observations should reflect what actually occurred. They should not become unsupported explanations used to dismiss a clinically important abnormality.

When an examination is technically limited, the report should communicate that limitation clearly.

A lower-quality examination should not automatically receive the same level of interpretive confidence as a technically satisfactory examination simply because its numerical values fall within the displayed reference range.

At the same time, a lower quality grade does not necessarily invalidate every measurement or prevent the result from contributing useful clinical information.

An abnormal measurement obtained under uncertain technical conditions should not automatically be treated as confirmation of disease.

The interpretation should explain what the examination supports, what remains uncertain and whether further clinical assessment or repeat testing may be appropriate.

This approach is consistent with the ERS/ATS emphasis on measurement uncertainty and the distinction between physiological findings and clinical diagnoses.

Measuring Spirometry Quality in Routine Practice

Healthcare organizations can improve spirometry reliability by monitoring the quality of examinations, not simply the number performed.

The distribution of technical quality grades can provide useful information about whether the service consistently obtains reliable measurements.

Organizations may monitor the proportion of sessions achieving specified ATS/ERS grades, with separate assessment of FEV1 and FVC where appropriate.

These findings should be interpreted in relation to patient age, examination purpose, clinical setting and the characteristics of the people being tested.

A service caring for patients with severe respiratory impairment may face different technical challenges from one providing routine occupational examinations.

A lower proportion of high-grade results does not automatically demonstrate poorer professional performance if patient populations and testing circumstances differ substantially.

Other useful measures include the proportion of examinations meeting repeatability criteria, the frequency of technical problems affecting acceptability and the completeness of documentation concerning reference equations and examination limitations.

Organizations may also review how often examinations need to be repeated because of inadequate technical quality.

Such measurements should distinguish repetition caused by technical problems from clinically justified reassessment performed to investigate changes in respiratory status.

Equipment quality assurance can be evaluated through completion of calibration verification and maintenance activities, recognition of out-of-tolerance findings and documentation of corrective action.

Operator competency assessment and periodic review of selected tracings may identify weaknesses that automated device reports do not capture.

However, healthcare organizations should avoid treating the percentage of grade A examinations as the sole measure of quality.

A service could improve its apparent performance by excluding patients who have difficulty completing spirometry or by failing to document unsuccessful attempts.

Such practices would undermine both diagnostic safety and equitable access.

A meaningful measurement program should retain information about incomplete examinations, the reasons for technical limitations and the actions taken when useful measurements cannot be obtained.

Where reference equations or software algorithms are changed, monitoring should also examine whether reports and clinical interpretations remain consistent with the revised settings.

Quality indicators become valuable when they help identify recurring problems, clarify contributing factors and demonstrate whether improvement activities have produced meaningful changes.

Governance and Professional Responsibilities

Spirometry reliability depends on coordination among the people performing examinations, those interpreting the findings and the organization responsible for the service.

Operators require appropriate training in patient coaching, maneuver assessment, recognition of technical problems and quality grading.

Professionals interpreting spirometry need sufficient expertise to evaluate physiological patterns, apply appropriate reference frameworks and recognize the limitations of individual results.

Equipment maintenance and technical support personnel contribute by ensuring that devices remain suitable for their intended use.

Clinical leadership and quality management teams can establish procedures for competency assessment, equipment oversight, reporting, incident review and continuous improvement.

These responsibilities should be clearly assigned.

An operator needs an appropriate mechanism for escalating concerns when a patient cannot complete a satisfactory examination or when equipment behaves unexpectedly.

Clinicians receiving a report should also have a way to request technical clarification when findings appear inconsistent with the clinical presentation.

Healthcare organizations should establish change management procedures covering spirometry software, device settings, reference equations and reporting templates.

A software update may alter predicted values, quality grading or automated interpretation without changing the patient's measured lung function.

Before implementing changes that could affect clinical interpretation, the organization should assess their likely consequences and undertake appropriate verification.

A governance system must also recognize that repeating spirometry is not always practical or safe.

Patients with severe symptoms, physical limitations, cognitive difficulties or other barriers may be unable to perform technically optimal maneuvers despite appropriate support.

The response should be clinically proportionate and respectful, including consideration of alternative investigations when necessary.

Applying International Guidance in Viet Nam

Spirometry is used in Viet Nam across respiratory medicine and other clinical services where objective assessment of lung function may support diagnosis and follow-up.

Healthcare organizations differ in equipment, testing volumes, specialist staffing and access to professionals experienced in pulmonary function assessment.

These differences make it important to translate international standards into practical arrangements rather than assume that every facility has identical resources.

The ATS/ERS 2019 spirometry standard and the ERS/ATS 2022 interpretation standard provide appropriate technical and professional references.

The 2026 GOLD/GLI joint statement adds updated guidance concerning the interpretation of airflow obstruction in suspected COPD.

Research by Tran and colleagues offers recent evidence from a Vietnamese hospital regarding the consequences of changing reference equations.

Together, these resources support an approach in which examination quality, reference equation selection, reporting practices and clinical interpretation are considered connected parts of the diagnostic process.

However, international professional standards do not automatically become statutory obligations for every healthcare organization operating in Viet Nam.

The relevant national legal framework includes the Law on Medical Examination and Treatment No. 15/2023/QH15, effective January 1, 2024, and Decree No. 96/2023/ND-CP, which provides detailed implementing provisions.

Circular No. 23/2024/TT-BYT establishes the lists of medical examination and treatment techniques.

It was amended by Circular No. 25/2026/TT-BYT, issued on June 30, 2026.

Although Circular No. 25/2026/TT-BYT generally took effect on August 15, 2026, its Articles 2 and 3 took effect on July 1, 2026.

Under the amended arrangements, the technical list in Appendix 01 of Circular No. 23/2024/TT-BYT continues to apply through December 31, 2027, while the list in Appendix 02 applies from January 1, 2028.

The implications for an individual spirometry service depend on the techniques authorized for the facility, relevant professional responsibilities and applicable licensing and regulatory provisions.

These instruments should not be interpreted as establishing a universal statutory requirement that every spirometry examination achieve a particular ATS/ERS quality grade.

However, the absence of a nationwide mandatory quality-grade threshold does not eliminate healthcare organizations' responsibilities to provide services within their authorized professional scope and maintain appropriate technical and clinical safeguards.

The presence of a spirometry device alone does not establish that a facility has all the necessary conditions to perform and interpret examinations reliably.

Where spirometry records are stored or transmitted electronically, patient confidentiality and information governance also need to be considered.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.

Healthcare organizations should assess the applicable requirements concerning lawful processing, confidentiality, authorized access, information security and the handling of identifiable health information.

For practical quality improvement, facilities may begin by reviewing equipment performance, operator competence, technical grading practices and the completeness of reports.

Larger services may establish routine audits and structured technical review programs. Smaller facilities can still strengthen reliability through standardized procedures, documented quality assessment and appropriate access to specialist advice.

The objective is to establish diagnostic reliability that can be demonstrated through evidence rather than assumed from equipment availability.

Turning Quality Measurement Into Practical Improvement

Consider a healthcare facility where spirometry reports frequently show reduced FVC values.

One possible conclusion might be that the service is seeing a high prevalence of restrictive lung disease. A more useful quality review would first examine whether the measurements are technically reliable.

Were patients able to complete expiration? Were the volume-time curves assessed? Did the sessions meet the relevant repeatability criteria? Was the quality grade documented? Were reference equations applied consistently?

The review might reveal that a proportion of patients were stopping expiration prematurely.

In that situation, an improvement intervention could focus on operator coaching, recognition of early termination and structured review of the relevant curves.

The organization could then reassess examination quality to determine whether the intervention improved the reliability of FVC measurements.

Another facility may encounter a different problem. After replacing its spirometry software, clinicians notice that predicted values and interpretation labels have changed despite similar measured values.

The problem may not involve deterioration in equipment performance or patient lung function. It may reflect changes to reference equations or software settings.

An appropriate response would involve verifying the configuration, reviewing potentially affected reports and ensuring that interpreting clinicians understand the implications.

These examples demonstrate why quality improvement should investigate the causes of unreliable information rather than treating every abnormal or unexpected result as evidence of disease.

Improvement also depends on feedback between professional groups.

Operators benefit from understanding how technical errors can influence clinical conclusions. Interpreting clinicians benefit from understanding the limitations of the measurements they receive.

Quality management and clinical governance teams can connect these observations with equipment oversight, staff development and performance monitoring.

Over time, this approach can make spirometry services more consistent and dependable.

Strengthening Spirometry Reliability as Part of Diagnostic Excellence

Spirometry is often described as a relatively simple and accessible diagnostic examination. Its clinical value, however, depends on a series of decisions that extend beyond the device.

The patient must be able to perform an appropriate maneuver. The operator must recognize whether measurements are technically acceptable or usable. Equipment must function reliably. The report must apply a justified reference framework, and the interpreting clinician must understand what the findings support and where uncertainty remains.

A weakness at any of these stages can reduce the diagnostic value of the examination.

International guidance and research available in 2026 provide a strong foundation for improving these processes.

The ATS/ERS standards define how technical quality should be assessed. The GOLD/GLI joint statement emphasizes clinical context and uncertainty when interpreting airflow obstruction. Recent research from Viet Nam demonstrates that reference equation selection can change the classification of spirometry results without changing the underlying measurements.

For healthcare organizations in Viet Nam, the priority should be to move beyond simply increasing the number of spirometry examinations performed.

An inadequate maneuver should not acquire diagnostic authority merely because its numbers appear in a report. A borderline FEV1/FVC ratio should not become a definitive disease diagnosis without appropriate clinical evidence. A change in predicted values after a reference equation update should not be mistaken for a change in the patient's health.

Reliable spirometry requires systems that recognize these distinctions and enable professionals to respond appropriately.

Diagnostic excellence in spirometry is not demonstrated by the number of examinations completed or the apparent precision of their numerical results. It depends on whether healthcare organizations can establish how much confidence each examination deserves, communicate its limitations accurately and continually improve the processes that make reliable clinical interpretation possible.

Selected References and Regulatory Sources

Graham BL, Steenbruggen I, Miller MR, et al. Standardization of Spirometry 2019 Update: An Official American Thoracic Society and European Respiratory Society Technical Statement. American Journal of Respiratory and Critical Care Medicine. 2019;200(8)–e88. DOI: 10.1164/rccm.201908-1590ST.

Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS Technical Standard on Interpretive Strategies for Routine Lung Function Tests. European Respiratory Journal. 2022;60(1):2101499. DOI: 10.1183/13993003.01499-2021.

Bhakta NR, Bime C, Kaminsky DA, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine. 2023;207(8):978–995. DOI: 10.1164/rccm.202302-0310ST.

Halpin DMG, Stanojevic S, McCormack MC, et al. Joint Statement From GOLD/GLI Regarding the Use of Spirometry to Define Airflow Obstruction and Diagnose COPD. European Respiratory Journal. 2026;67(4):2502574. DOI: 10.1183/13993003.02574-2025.

Tran DTT, Le-Đong NN, Nguyen-Xuan T, et al. Impacts of Race-Neutral GLI Reference Equations on Spirometry Interpretation in a Southeast Asian Population. Respiratory Medicine. 2026;263:109157. Published online September 10, 2026. DOI: 10.1016/j.rmed.2026.109157.

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Prevention, Diagnosis and Management of COPD: 2026 Report.

International Organization for Standardization. ISO 26782:2009: Anaesthetic and Respiratory Equipment: Spirometers Intended for the Measurement of Time Forced Expired Volumes in Humans. Published edition. Revision under development as of November 2026.

NHS England. Commissioning Standards for Spirometry. First published September 24, 2024. Updated March 3, 2026.

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. Effective January 1, 2024, as amended.

Government of Viet Nam. Decree No. 96/2023/ND-CP, Detailing Certain Articles of the Law on Medical Examination and Treatment. December 30, 2023.

Ministry of Health of Viet Nam. Circular No. 23/2024/TT-BYT, Promulgating the List of Medical Examination and Treatment Techniques. October 18, 2024, as amended.

Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, Amending and Supplementing Certain Provisions of Circular No. 01/2013/TT-BYT, Circular No. 32/2023/TT-BYT, Circular No. 23/2024/TT-BYT and Circular No. 42/2025/TT-BYT. June 30, 2026. Articles 2 and 3 effective July 1, 2026; general effective date August 15, 2026.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Measures for Implementing the Law on Personal Data Protection. Effective January 1, 2026.

Professional Scope and Disclaimer

This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement and quality improvement.

The content is intended for general professional education and discussion. It does not constitute patient-specific medical advice, a clinical diagnosis, a treatment protocol, an individualized recommendation concerning spirometry procedures, reference equations, diagnostic thresholds or additional investigations, a determination of professional or technical error, an accreditation assessment or legal advice.

The discussion primarily addresses routine diagnostic spirometry. Pediatric testing, occupational surveillance, preoperative evaluation, advanced pulmonary function testing and other specialized clinical settings may require additional professional and technical considerations.

References to ATS, ERS, GOLD, GLI, ISO and other international guidance do not imply endorsement of this article by the organizations concerned or establish that every recommendation is legally mandatory in Viet Nam.

The applicability of technical standards, professional guidance and Vietnamese legal requirements depends on the healthcare organization's authorized professional activities, licensing arrangements, relevant regulations and any applicable accreditation or contractual commitments.

Decisions concerning spirometry performance, equipment quality assurance, reference equation selection, clinical interpretation and further patient assessment must be undertaken by appropriately qualified and authorized professionals in accordance with applicable Vietnamese law, relevant professional standards and the patient's clinical circumstances.

Diagnostic Excellence Vietnam does not provide spirometry testing, individualized clinical diagnosis or treatment services through this educational publication.